Overview

HAIC Combined With Camrelizumab Plus Rivoceranib for Advanced Mixed Hepatocellular-cholangiocarcinoma (HCC-CCA)

Status:
RECRUITING
Trial end date:
2028-08-01
Target enrollment:
Participant gender:
Summary
To evaluate HAIC combined with Camrelizumab plus rivoceranib for advanced mixed hepatocellular-cholangiocarcinoma (HCC-CCA).
Phase:
PHASE2
Details
Lead Sponsor:
Fudan University
Treatments:
apatinib
camrelizumab